Patents by Inventor David Allis
David Allis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220169980Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.Type: ApplicationFiled: September 2, 2021Publication date: June 2, 2022Applicants: Memorial Sloan Kettering Cancer Center, The Rockefeller UniversityInventors: Lydia W.S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
-
Patent number: 11203739Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.Type: GrantFiled: April 7, 2015Date of Patent: December 21, 2021Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller UniversityInventors: Lydia W. S. Finley, Bryce W. Carey, Craig B. Thompson, C. David Allis
-
Patent number: 9388213Abstract: The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity.Type: GrantFiled: September 10, 2013Date of Patent: July 12, 2016Assignee: The Rockefeller UniversityInventors: C. David Allis, Peter Lewis
-
Patent number: 8404458Abstract: The present invention relates to a method of modulating a chromatin binding protein or complex which binds to a functional group on an amino acid of a histone. This method involves phosphorylating or dephosphorylating a serine or threonine on the histone proximate to the amino acid under conditions effective to modulate the chromatin binding protein or complex. This method is particularly useful in treating or preventing cancer in a subject. In addition, the histone comprising a serine or threonine proximate to an amino acid capable of binding to a functional group can be used to screen for compounds which prevent or treat cancer. Also disclosed is an antibody or binding portion thereof raised against a binary switch on a histone comprising a phosphorylated serine or threonine proximate to an amino acid bound to a functional group and its use in detecting a condition mediated by that switch.Type: GrantFiled: September 15, 2004Date of Patent: March 26, 2013Assignee: The Rockefeller UniversityInventors: C. David Allis, Wolfgang Fischle, Holger Dormann
-
Publication number: 20110312897Abstract: Methods and agents useful for modulating histone proteolysis, stem cell differentiation, and gene transcription and for treating cancer are disclosed. Antibodies or antigen binding fragments that selectively bind to histone-3 cleavage products and are useful for diagnosing cancer and monitoring a subject's response to cancer treatment are also disclosed.Type: ApplicationFiled: September 17, 2009Publication date: December 22, 2011Applicant: THE ROCKEFELLER UNIVERSITYInventors: C. David Allis, Elizabeth Duncan
-
Publication number: 20110088332Abstract: A modular closet unit comprising a structure of upright frame members connected between a floor and a ceiling of an occupied space, a horizontal track between the upright frame members, and bifold doors for closing the space between the upright frame members and between the horizontal track and the floor. The modular closet unit further includes fascia panels positioned above the bifold doors and side panels positioned at one or more ends of the modular closet unit.Type: ApplicationFiled: October 19, 2010Publication date: April 21, 2011Inventors: David Allis, Beverley Shelley, William Bookman, Chad Carver, Randy Windham, Susan Jacobs, Oscar Hughes
-
Patent number: 7851175Abstract: The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enzymatically acetylated or deacetylated.Type: GrantFiled: October 13, 2009Date of Patent: December 14, 2010Assignees: The Board of Trustees of the University of Arkansas, The Rockefeller UniversityInventors: Alan J. Tackett, C. David Allis, Sean D. Taverna
-
Publication number: 20100080799Abstract: The present invention relates to methods of detecting and regulating cellular DNA damage as well as methods of screening compounds suitable for modulating cellular DNA damage. The methods of the present invention utilize antibodies that selectively bind to a phosphorylated tyrosine residue in a SQEY tyrosine phosphorylation motif sequence or a phosphorylated serine residue in a KENSSQ phosphorylation motif sequence, where the phosphorylated serine residue is closest to the glutamine residue. Also encompassed by the present invention are methods of treating a subject having cancer. These methods involve the administration of an agent that modulates the phosphorylation of the tyrosine residue in a SQEY motif. Suitable agents for modulating the phosphorylation of the tyrosine residue of the SQEY motif are also disclosed.Type: ApplicationFiled: September 17, 2009Publication date: April 1, 2010Applicant: THE ROCKEFELLER UNIVERSITYInventors: C. David Allis, Andrew Xiao
-
Patent number: 7670795Abstract: The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enzymatically acetylated or deacetylated.Type: GrantFiled: June 12, 2007Date of Patent: March 2, 2010Inventors: Alan J. Tackett, C. David Allis, Sean D. Taverna
-
Publication number: 20100041085Abstract: The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enyzmatically acetylated or deacetylated.Type: ApplicationFiled: October 13, 2009Publication date: February 18, 2010Inventors: Alan J. Tackett, C. David Allis, Sean D. Taverna
-
Publication number: 20090061469Abstract: The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enzymatically acetylated or deacetylated.Type: ApplicationFiled: June 12, 2007Publication date: March 5, 2009Inventors: Alan J. Tackett, C. David Allis, Sean D. Taverna
-
Publication number: 20040197838Abstract: The present invention is directed to the generation of antibodies against an &agr;-phosphorylated serine 14 residue on Histone 2B. This postranslational modification of the amino terminus of Histone 2B is associated with cells that are about to enter or are already undergoing apoptosis. These antibodies are useful in identifying apoptotic cells and serve as diagnostic and screening tools. The present invention is also directed to the Mst1 kinase and the isolation of compounds that modulate the activity of Mst1. This kinase has been identified as the enzyme responsible for creating this postranslational modification on Histone 2B in vivo.Type: ApplicationFiled: January 30, 2004Publication date: October 7, 2004Inventors: C David Allis, Wang L Cheung, Ajiro Kozo
-
Publication number: 20040186274Abstract: The present invention relates to the generation of antibodies that bind to specific modifications of the amino terminus of histone H3 and H2A peptides. More particularly, the present invention is directed to the generation of a set of antibodies that recognize various post-tanslational modifications of a histone modification cassette SGRGK (SEQ ID NO: 1), wherein the modifications are selected from the group consisting of a phosphorylated serine, methylated arginine and acetylated lysine. Compositions comprising these antibodies are used as diagnosed and screening tools.Type: ApplicationFiled: January 2, 2004Publication date: September 23, 2004Inventors: C. David Allis, Scott D. Briggs, Brian D. Strahl
-
Publication number: 20040053848Abstract: The present invention related to the generation of methyllysine-specific histone antibodies. In particular, the H3 lysine 4 methylation specific antibody (Methyl(K4)H3) binds to histone H3 methylated at lysine 4. Methylation of lysine 4 (K4) on histone H3 has been associated with transcriptionally active regions of chromatin. A second antibody, H3 lysine 9 methylation specific antibody (Methyl(K9)H3) specifically binds to histone H3 methylated at lysine 9. Methylation of lysine 9 (K9) on histone H3 has been associated with gene silencing. These antibodies are useful in identifying regions of heterochromatin and euchromatin and serving as diagnostic and screening tools.Type: ApplicationFiled: February 14, 2003Publication date: March 18, 2004Inventors: C. David Allis, Brian D. Strahl
-
Patent number: 5137227Abstract: A fishing reel having a reel body, a rear cover defining a receptacle for the reel body, a front cover, structure for releasably connecting the front and rear covers for maintaining the reel body captively within the rear cover receptacle, and structure for releasably connecting the reel body to one of the front and rear covers.Type: GrantFiled: October 23, 1990Date of Patent: August 11, 1992Assignee: Zebco CorporationInventors: David Allis, Thomas A. Pulliam
-
Patent number: 4984665Abstract: An anti-reverse actuator for a reel of the type having a line carrying spool, a crank assembly consisting of a crank shaft and a handle operable to rotate the crank shaft about an axis, structure responsive to rotation of the crank handle in a first direction for directing line onto the spool, a pawl mounted for movement between first and second positions, structure for blocking the pawl in the first and second positions, and structure on the crank assembly for engaging the pawl in the first position so that the pawl prevents rotation of the crank handle in a second direction opposite to the first direction and for allowing the crank handle to rotate oppositely to the first direction with the pawl in the second position.Type: GrantFiled: December 14, 1989Date of Patent: January 15, 1991Assignee: Zebco CorporationInventor: David Allis